Device Trial Radar · NCT05500846
Targeted Cryoablation of Prostate Cancer Lesions: An Investigator-initiated Trial
Last checked: Nov 19, 2026Latest source record: Jun 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
51
Actual
Start
Oct 19, 2021
Primary completion
Nov 14, 2023
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- Osamu UkimuraAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 15, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Male only, from 20 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is to provide a minimally invasive treatment option in which the targeted prostate cancer tissue is killed by cryoablation at extremely low temperatures only in the specific area of cancer "that should be treated for saving of life"; while, leaving a portion of the normal prostate tissue that is not cancerous. It is a treatment, named by "focal therapy" for "clinically localized prostate cancer". As this new treatment is aiming to treat only specific prostatic area of cancer, it is different from the invasive conventional treatment to remove the entire prostate gland. The goal is to achieve both to control of known cancer by treating only the cancerous area and to maintain of QOL (Quality-of-life) by leaving of the other normal prostate tissue and its surrounding organs intact resulting in prevention of urinary-leakage and sexual-dysfunction as the complications.
Conditions
- Prostate Cancer
Interventions
The Visual Ice Cryoablation SystemDevice
Currently, the standard surgical treatment option for localized prostate cancer is total prostatectomy, which removes the entire prostate organ. However, total prostatectomy is invasive and postoperative urinary incontinence, sexual dysfunction and local recurrence remain clinical challenges even with the introduction of robotic assistance techniques. Cryotherapy has been approved as one of the other surgical treatment options for localized prostate cancer in the USA and Europe, but not in Japan. This clinical trial aims to expand the indication of cryotherapy equipment, which has already been approved for insurance for renal cancer, to prostate cancer in Japan. In this clinical trial, Focal Therapy will be performed by targeting a single localized prostate cancer lesion visualized by MRI. By targeting cancer lesions in a minimally invasive manner, we aim to achieve both control of cancer lesions and maintenance of quality of life.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disappearance of cancer at 6 month after cryosurgery evaluated by combination of the responses in PSA, MRI, and Prostate biopsyTime frame: 6 months after the cryosurgery
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University Hospital, Kyoto Prefectural University of Medicine
Kyoto, Japan
Kyoto Miniren Chuo Hospital
Kyoto, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.